Blood Platelets Market By Product Type (Leukoreduced Platelets, Pooled Platelets, Single Donor Platelets), By End-User Industry (Hospitals, Blood Banks, Diagnostic Laboratories, Research Institutes), By Technology (Apheresis Platelet Collection, Whole Blood Platelet Collection), By Application (Trauma & Surgical Patients, Cancer & Hematology Patients, Bone Marrow Disorders); Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Blood Platelets Market was valued at USD 3.8 billion in 2023 and will surpass USD 6.5 billion by 2030; growing at a CAGR of 8.0% during 2024 - 2030. The blood platelets market plays a pivotal role in the healthcare industry, particularly in critical care settings where platelet transfusions are required to treat patients suffering from bleeding disorders or trauma. Platelets, essential for blood clotting and wound healing, are increasingly being used for patients with conditions like leukemia, hemophilia, and trauma-induced bleeding. The market is driven by advancements in collection technologies, improvements in storage methods, and a growing demand for blood products worldwide. As the healthcare sector continues to evolve, the need for safe, effective, and readily available blood platelets remains paramount. Leukoreduced Platelets Segment is Largest Owing to Increased Safety and Demand The leukoreduced platelets segment is the largest in the blood platelets market due to its enhanced safety and reduced risk of transfusion reactions. Leukoreduction, which involves filtering out white blood cells from platelets, helps minimize immune responses such as febrile non-hemolytic reactions and transfusion-related acute lung injury (TRALI). This has made leukoreduced platelets a preferred option for patients requiring frequent transfusions. The growing awareness of these safety benefits, coupled with the rising demand for platelet transfusions in hospitals and blood banks, is expected to sustain the dominance of this subsegment. The increasing prevalence of chronic conditions, such as cancer and hematologic disorders, which necessitate frequent platelet transfusions, further supports the growth of the leukoreduced platelets subsegment. In addition, hospitals and blood banks are focusing on adopting safer blood products to improve patient outcomes. These factors combined make leukoreduced platelets an essential component in transfusion medicine, driving the market's growth in this segment. Blood Banks Segment is Largest Due to High Demand for Platelets Blood banks dominate the end-user industry segment of the blood platelets market owing to their critical role in collecting, processing, and distributing blood and its components. Blood banks play a crucial role in ensuring a continuous supply of platelets for hospitals, clinics, and other healthcare institutions, where they are needed for a variety of conditions, including trauma, surgeries, and chronic diseases such as cancer. The infrastructure and operations of blood banks are well-established to meet the high demand for blood platelets, making them the largest end-user segment. As the need for blood products increases due to growing populations and healthcare advancements, blood banks are increasingly focused on improving the efficiency of their collection and distribution processes. The integration of advanced blood collection and storage technologies is helping blood banks maintain a steady supply of platelets, thus reinforcing their position as the largest end-user segment in the market. Apheresis Platelet Collection Technology is Fastest Growing Due to Efficiency and Quality Among the various technologies used for platelet collection, apheresis technology is the fastest-growing due to its superior efficiency and ability to produce higher-quality platelets. Apheresis platelet collection allows for the collection of platelets from a single donor, ensuring a more concentrated supply of platelets compared to traditional whole blood donation. This technology is gaining momentum due to its ability to reduce donor exposure, increase platelet yield, and enhance the quality of transfusions. The adoption of apheresis is growing particularly in regions with a well-established blood donation infrastructure, where there is a strong emphasis on optimizing the donation process. Apheresis platelet collection is also more cost-effective in the long term as it minimizes the need for multiple donors and ensures a more targeted treatment approach. This growth is fueled by the increasing awareness of apheresis's benefits and its adoption in hospitals and blood banks globally. As healthcare systems look for more sustainable and effective solutions, apheresis platelet collection technology is expected to continue its rapid growth. Trauma and Surgical Patients Application is Largest Owing to High Demand for Platelet Transfusions The trauma and surgical patients application segment is the largest in the blood platelets market due to the critical need for platelets in emergency and surgical care. Platelet transfusions are essential in trauma cases where severe blood loss occurs, as well as in surgeries that involve extensive blood loss. The demand for platelets in these cases is high, as platelets play a crucial role in blood clotting and preventing excessive bleeding. As the global incidence of trauma-related injuries and complex surgeries increases, the need for platelet transfusions continues to grow. The use of blood platelets in trauma and surgical cases is expected to remain a significant driver for the market, particularly with the increasing number of road accidents, surgical procedures, and trauma cases worldwide. The growing sophistication of surgical techniques and advancements in trauma care are further contributing to the demand for blood platelets, reinforcing the prominence of this application segment. North America Region is Largest Due to Advanced Healthcare Infrastructure North America holds the largest share of the blood platelets market due to its well-established healthcare infrastructure, high healthcare spending, and advanced medical technologies. The demand for blood platelets in North America is driven by the region’s high incidence of chronic diseases such as cancer, leukemia, and other hematologic conditions, which require frequent platelet transfusions. Additionally, the presence of key market players, regulatory bodies, and healthcare providers in the region facilitates the rapid availability and distribution of blood platelets. Furthermore, North American countries like the United States and Canada have robust blood donation and transfusion systems in place, with sophisticated blood collection technologies and extensive research in hematology. These factors contribute to North America’s dominance in the global blood platelets market and its ability to meet the growing demand for platelet transfusions. Competitive Landscape and Leading Companies The blood platelets market is highly competitive, with key players like Grifols, CSL Behring, Haemonetics Corporation, and Terumo BCT leading the industry. These companies have developed advanced technologies for platelet collection, storage, and transfusion, ensuring the highest quality and safety standards. Many of the leading players are also focused on expanding their global presence through strategic acquisitions, partnerships, and innovation in platelet-related technologies. Additionally, regional players and emerging companies are entering the market, contributing to the overall growth of the industry. As healthcare systems worldwide continue to address the increasing demand for blood products, competition in the blood platelets market is expected to intensify, with companies focusing on technological advancements, cost efficiency, and improving patient outcomes to maintain their market position. Recent Developments: • Grifols announced the launch of a new blood plasma collection device, which is expected to improve the efficiency and safety of platelet collection, reducing donor discomfort and increasing plasma supply. • CSL Behring expanded its partnership with the American Red Cross to improve blood platelet availability for hospitals across the United States, particularly in times of emergency or shortage. • Fresenius Kabi received regulatory approval from the European Medicines Agency (EMA) for a new platelet storage solution, enhancing the shelf life and viability of platelets for transfusion. • Haemonetics Corporation unveiled a next-generation apheresis system designed to improve the collection and processing of blood platelets, promising better outcomes for both donors and patients. • Terumo BCT entered into a strategic acquisition of a platelet-related technology company, enhancing its portfolio of apheresis products to meet the growing demand for blood platelets globally. List of Leading Companies: • Grifols • CSL Behring • Baxter International Inc. • Terumo BCT • Fresenius Kabi • Octapharma • Haemonetics Corporation • BloodCenter of Wisconsin • China National Pharmaceutical Group (Sinopharm) • Bio Products Laboratory • Progenika Biopharma • Medline Industries • Hospital Corporation of America (HCA Healthcare) • The American Red Cross • Sanquin Blood Supply Foundation Report Scope: Report Features Description Market Size (2023) USD 3.8 Billion Forecasted Value (2030) USD 6.5 Billion CAGR (2024 – 2030) 8.0% Base Year for Estimation 2023 Historic Year 2022 Forecast Period 2024 – 2030 Report Coverage Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments Segments Covered Blood Platelets Market By Product Type (Leukoreduced Platelets, Pooled Platelets, Single Donor Platelets), By End-User Industry (Hospitals, Blood Banks, Diagnostic Laboratories, Research Institutes), By Technology (Apheresis Platelet Collection, Whole Blood Platelet Collection), By Application (Trauma & Surgical Patients, Cancer & Hematology Patients, Bone Marrow Disorders) Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) Major Companies Grifols, CSL Behring, Baxter International Inc., Terumo BCT, Fresenius Kabi, Octapharma, Haemonetics Corporation, BloodCenter of Wisconsin, China National Pharmaceutical Group (Sinopharm), Bio Products Laboratory, Progenika Biopharma, Medline Industries, Hospital Corporation of America (HCA Healthcare), The American Red Cross, Sanquin Blood Supply Foundation Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements